Eton Pharmaceuticals, Inc. Income Taxes Paid
Eton Pharmaceuticals, Inc. (ETON) reported Income Taxes Paid of $85.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. income taxes paid for the quarter ending 2026-06-30 was $48.00K, a 40.74% decline year-over-year.
- Eton Pharmaceuticals, Inc. income taxes paid for the quarter ending 2026-03-31 was $37.00K, a 362.50% increase year-over-year.
- Eton Pharmaceuticals, Inc. income taxes paid for the quarter ending 2025-09-30 was $28.00K.
- Eton Pharmaceuticals, Inc. income taxes paid for the quarter ending 2025-06-30 was $81.00K.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month |
|---|---|---|---|
| 2026-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $85.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $37.00K 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $109.00K derived: sum of 2 quarters · filed 2026-08-13 | $117.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $89.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $8.00K 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | $181.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |